
Repare Therapeutics Presents Phase 1 Data on Camonsertib and Radiotherapy at ASTRO Annual Meeting
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, today shared data showcasing the clinical benefits of camonsertib, a promising oral small molecule ATR inhibitor, used in combination with…











